European Archives - Page 329 of 1053 - European Medical Journal

EMJ Rheumatology 10.1 2023

We are excited to announce the latest issue of EMJ Rheumatology, including a review of the European Alliance of Associations for Rheumatology (EULAR) 2023 Congress, highlighting key sessions from the event.

Prevalence of Risk for Anxiety and Depression in Patients with Rheumatic Diseases

There is a higher prevalence of anxiety and depression in patients with chronic diseases. In a complex relationship, chronic diseases and…

Work Participation and the COVID-19 Pandemic: A Study Within the Amsterdam COVID-19 Cohort Among People with Inflammatory Rheumatic Diseases and Population Controls

Past research has repeatedly shown that patients with inflammatory rheumatic disease (IRD) experience restrictions in work participation.

Predictors of Renal Flares in Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with a highly heterogenous clinical presentation that can affect…

Interactive Study on Diagnosis and Management of Endometrial Cancer

This interactive study describes the incidence, epidemiology, diagnosis, staging, and risk assessment of endometrial cancer, and…

Are Myosin Inhibitors the Future of HCM Management?

This podcast episode explores new advances in treating obstructive hypertrophic cardiomyopathy (HCM) and the role of myosin inhibitors.

Evolving the treatment paradigm in cold agglutinin disease (CAD): Challenges and opportunities for optimal management

Prof. Alexander Röth (Chair), Prof. Wilma Barcellini, Prof. Josephine Vos and Prof. Bernd Jilma, will discuss about the evolving treatment paradigm in cold agglutinin disease (CAD): challenges and opportunities for optimal management.

Karen Pinachyan

Meet GOLD’s new catalyst – CSL Behring’s Karen Pinachyan

In this week’s episode, Isabel and Jade share some snippets from the interview with GOLD’s next catalyst Karen Pinachyan, Head of Medical Affairs, Europe, CSL Behring.

Sickle Cell Disease

This infographic gives informative statistics and explores the current prevalence of sickle cell disease globally, it also provides…

What to do when CAR Ts are not the most appropriate option in 2L DLBCL: Current treatment options for transplant-ineligible patients

An innovative session highlighting patient-focused decision-making and a dynamic debate on current 2L DLBCL treatment options.